chlormadinone acetate has been researched along with Disease Exacerbation in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amao, R; Goto, J; Haga, N; Ichikawa, Y; Maeno, T; Ohtsu, H; Taguri, M; Tsuji, S; Yamamoto, T; Yokota, K | 1 |
| Takeuchi, S; Yoshida, K | 1 |
| Akakura, K; Akimoto, S; Inomiya, H; Ito, H; Shimazaki, J | 1 |
| Itoh, K; Kubota, Y; Nakada, T; Sasagawa, I; Suzuki, H; Yanai, H | 1 |
| Furuya, Y; Fuse, H; Nagakawa, O; Nozaki, T | 1 |
2 trial(s) available for chlormadinone acetate and Disease Exacerbation
| Article | Year |
|---|---|
An open trial of long-term testosterone suppression in spinal and bulbar muscular atrophy.
Topics: Adult; Androgen Antagonists; Chlormadinone Acetate; Delayed-Action Preparations; Disease Progression; Humans; Knee; Leuprolide; Longitudinal Studies; Male; Middle Aged; Muscle Strength; Muscle Weakness; Muscular Disorders, Atrophic; Prospective Studies; Treatment Outcome | 2013 |
Pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing-hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma; Chlormadinone Acetate; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Premedication; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 1995 |
3 other study(ies) available for chlormadinone acetate and Disease Exacerbation
| Article | Year |
|---|---|
Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlormadinone Acetate; Cisplatin; Disease Progression; Estrogens; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Karnofsky Performance Status; Lactates; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Orchiectomy; Progesterone Congeners; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Rate | 1997 |
The prognosis of stage A patients treated with the antiandrogen chlormadinone acetate.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Chlormadinone Acetate; Disease Progression; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Aged; Progesterone Congeners; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Rate | 1999 |
Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chlormadinone Acetate; Diethylstilbestrol; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Statistics, Nonparametric; Testosterone; Tosyl Compounds | 2002 |